Arterial Hypertension Clinical Trial
— LÄRMOfficial title:
The Influence of Aircraft Noise Exposure on Renal Hemodynamic in Healthy Individuals
Verified date | February 2018 |
Source | University of Erlangen-Nürnberg Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Epidemiological studies have found a link between aircraft noise exposure and increased incidence of arterial hypertension and thus cardiovascular disease. The underlying pathophysiological mechanisms are not yet fully understood. The kidney acts as a long-term regulator of blood pressure and controls the extracellular sodium and water balance. Significant renal mechanisms of blood pressure regulation are the renin angiotensin system, renal sympathetic activity and sodium excretion. Animal work and clinical studies show that mental stress affects the renal plasma flow and urinary sodium excretion. The investigators observed a lower sodium excretion in situations of mental stress in subjects at risk for developing arterial hypertension. In healthy volunteers, a 30-minute mental stress test resulted in increased glomerular filtration rate, filtration fraction and an increase in urinary sodium excretion. In this pilot study the investigators analyzed the influence of 30 minutes standardized aircraft noise on renal and central hemodynamics.
Status | Completed |
Enrollment | 86 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Patients with mild-moderate arterial hypertension (grade 1-2) - Informed consent in writing available - Willing and able to comply with all requirements of the study - Male, between 18 and 50 years (inclusive) - Body Mass Index (BMI) 18-27 kg/m2 - Non-smoker - Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis). Minor deviations of laboratory values, ECG, and vital sign parameters from the normal range may be accepted, if judged by the Investigator to have no clinical relevance. Additional inclusion criteria for the cohort with arterial hypertension: - uncomplicated arterial hypertension WHO grade 1-2, office blood pressure 140-179/90-109 mmHg Exclusion Criteria for healthy individuals: - Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgement). - S-GOT or S-GPT levels > 2-times above the upper limit of normal range. - eGFR < 60 ml/min/1,73m2 or kidney stones - Clinically significant history of cardiovascular disease or any known present cardiovascular disease. - History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders. - Office blood pressure at screening higher than 140/100 mmHg - Office heart rate at screening outside the range of 50-99 beats per minute (inclusive). - Regular intake of medication within 1 month prior to study inclusion - Participation in any other clinical study within 30 days prior to inclusion in this study. - Clinically significant diseases (as judged by the investigator) within four weeks prior to screening - History of alcohol or drug abuse. Exclusion criteria for patients with arterial hypertension: - Regular intake of medication within 1 month prior to study inclusion - office blood pressure at screening visit > 180/110 mmHg - secondary hypertension application of - antihypertensive medication within 14 days prior to study inclusion - of "other" medication - Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgement). - S-GOT or S-GPT levels > 2-times above the upper limit of normal range. - eGFR < 60 ml/min/1,73m2 or kidney stones - Clinically significant history of cardiovascular disease or any known present cardiovascular disease other than arterial hypertension. - History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders, other than arterial hypertension. - Office heart rate at screening outside the range of 50-99 beats per minute (inclusive). - Regular intake of medication within 1 month prior to study inclusion - Participation in any other clinical study within 30 days prior to inclusion in this study. - Clinically significant diseases (as judged by the investigator) within four weeks prior to screening, other than arterial hypertension. - History of alcohol or drug abuse. |
Country | Name | City | State |
---|---|---|---|
Germany | University of Erlangen-Nuremberg | Erlangen | Bavaria |
Lead Sponsor | Collaborator |
---|---|
University of Erlangen-Nürnberg Medical School |
Germany,
A. Jumar, C. Ott, J.M. Harazny, K. Striepe, M.V. Karg, R.E. Schmieder. NEW MODEL TO INVESTIGATE THE INFLUENCE OF AIRCRAFT NOISE IN THE PATHOPHYSIOLOGICAL CONCEPT OF HYPERTENSION J Hypertens 2017;35, e-Supplement 2:e214 PP.15.32
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in renal plasma flow (l/min) | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05684055 -
"Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2)
|
N/A | |
Active, not recruiting |
NCT05436730 -
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy
|
||
Not yet recruiting |
NCT03294070 -
Fimasartan Plus Amlodipine on Hemodynamic Parameters and Arterial Stiffness in Patients With Hypertension
|
Phase 4 | |
Recruiting |
NCT01959997 -
Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI
|
Phase 2 | |
Completed |
NCT00983632 -
Selective Vagus Nerve Stimulation in Human
|
N/A | |
Recruiting |
NCT06098300 -
Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension
|
||
Completed |
NCT04564118 -
A Retrospective Analysis of the Adherence to Clinical Practice Guidelines Using the "MedicBK" Digital Platform in Patients With Hypertension and Atrial Fibrillation
|
||
Terminated |
NCT04677322 -
TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA
|
||
Completed |
NCT04278001 -
Clinical Usefullness of the Cuffless SOMNOtouch NIBP Device for 24-hour Ambulatory Blood Pressure Measurement
|
N/A | |
Withdrawn |
NCT03047538 -
Fixed Combination for Lipid and Blood Pressure Control
|
Phase 4 | |
Completed |
NCT03046264 -
Invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis
|
N/A | |
Completed |
NCT02620995 -
Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02041832 -
Detection of Subclinical Atrial Fibrillation in High Risk Patients Using Implantable Loop Recorder
|
N/A | |
Completed |
NCT01459120 -
Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho
|
N/A | |
Completed |
NCT01546181 -
Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases
|
||
Recruiting |
NCT01132001 -
Ambulatory Versus Home Blood Pressure Measurement
|
N/A | |
Completed |
NCT01454583 -
Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
|
N/A | |
Recruiting |
NCT03917758 -
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
|
N/A | |
Completed |
NCT03722524 -
The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension
|
||
Completed |
NCT03539627 -
Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.
|